Study identification

EU PAS number

EUPAS35296

Study ID

35854

Official title and acronym

Association of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) on coronavirus disease (COVID-19) incidence and complications

DARWIN EU® study

No

Study countries

Korea, Republic of
Spain
United Kingdom
United States

Study description

This study will evaluate the effect of ACE inhibitor or ARB exposure on the risk of contracting COVID-19 infection and the risk of experiencing respiratory failure, pneumonia, acute kidney injury, and death in hypertensive patients following contracting COVID-19 infection. The analysis will be undertaken across a federated multi-national network of electronic health records and administrative claims from primary care and secondary care that have been mapped to the Observational Medical Outcomes Partnership Common Data Model in collaboration with the Observational Health Data Sciences and Informatics (OHDSI) and European Health Data and Evidence Network (EHDEN) initiatives.

Study status

Finalised
Research institutions and networks

Institutions

University of Dundee
United Kingdom
First published:
01/02/2024
Institution Educational Institution
Ajou University South Korea, Columbia University US, Erasmus University Medical Centre The Netherlands, Janssen Research and Development US, UCLA US, University of Dundee UK, University of Oxford UK, University of South Australia Australia

Contact details

Marc Suchard

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
EU institutional research programme

More details on funding

EHDEN
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable